Tanvex BioPharma acquires Bora Biologics to expand biologics capabilities globally.
Tanvex BioPharma has acquired Bora Biologics, a subsidiary of Bora Pharmaceuticals. The merger combines Tanvex's expertise in biosimilar development in San Diego with Bora's early-stage biologics capabilities in Taiwan. Operating under the name Bora Biologics, the new entity will provide efficient end-to-end solutions for biologics clients globally, maintaining Tanvex's biosimilar product line under its own brand.
2 months ago
5 Articles
You have 5 free stories remaining this month. Subscribe anytime for unlimited access.